Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It acts by enhancing the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor, resulting in a decrease in neuronal excitability.
### Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
### Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability, not to exceed 20 mg twice daily.
* **Usual Maintenance Dose:** 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
### Pediatric Dosing
* **2 to less than 10 years of age:**
* **Initial Dose:** 5 mg once daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Usual Maintenance Dose:** 5 mg to 10 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg/day).
* **10 years of age and older:** Dosing is the same as for adults.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider starting at the lower end of the dosing range and titrating slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider starting at the lower end of the dosing range and titrating slowly.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, fatigue, lethargy, decreased appetite, constipation, diarrhea, increased drooling, agitation, irritability, aggression, upper respiratory tract infection, pneumonia, and falls.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome), withdrawal symptoms upon discontinuation, suicidal behavior or ideation.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** May increase clobazam plasma concentrations. Consider a dose reduction of clobazam.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam plasma concentrations. Consider a dose increase of clobazam.
* **Clobazam is a moderate inhibitor of CYP2C19:** May increase plasma concentrations of drugs metabolized by CYP2C19 (e.g., proton pump inhibitors like omeprazole).
### Monitoring
* Monitor for somnolence, fatigue, and other CNS effects.
* Monitor for behavioral changes, including suicidal ideation and behavior.
* Monitor for signs and symptoms of withdrawal if discontinuing the medication.
* Monitor seizure frequency and severity.
* Therapeutic drug monitoring of clobazam levels is generally not required but may be considered in specific clinical situations.
### Clinical Pearls
* Clobazam should be withdrawn gradually to avoid withdrawal symptoms.
* Due to the risk of serious skin reactions, educate patients and caregivers to discontinue clobazam immediately and seek medical attention if a rash develops.
* Clobazam may cause dose-dependent central nervous system depression.
***
*Disclaimer: This information is intended for clinical professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant literature before making any treatment decisions.*
